ENTRY       D12177                      Drug
NAME        Teclistamab (USAN/INN);
            Teclistamab-cqyv;
            Tecvayli (TN)
PRODUCT     TECVAYLI (Janssen Biotech)
FORMULA     C6383H9847N1695O2003S40
EXACT_MASS  143571.9603
MOL_WEIGHT  143660.238
SEQUENCE    (Heavy chain)
            QLQLQESGPG LVKPSETLSL TCTVSGGSIS SGSYFWGWIR QPPGKGLEWI GSIYYSGITY
            YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARH DGAVAGLFDY WGQGTLVTVS
            SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEAAGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE
            GNVFSCSVMH EALHNHYTQK SLSLSLGK
            (Light chain)
            SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQPPG QAPVVVVYDD SDRPSGIPER
            FSGSNSGNTA TLTISRVEAG DEAVYYCQVW DSSSDHVVFG GGTKLTVLGQ PKAAPSVTLF
            PPSSEELQAN KATLVCLISD FYPGAVTVAW KGDSSPVKAG VETTTPSKQS NNKYAASSYL
            SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
            (heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR IRSKYNNYAT
            YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR HGNFGNSYVS WFAYWGQGTL
            VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA
            GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ
            FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ
            EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFL LYSKLTVDKS
            RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK
            (light chain)
            QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI GGTNKRAPGT
            PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF GGGTKLTVLG QPKAAPSVTL
            FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
            LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
            (Disulfide bridge: H22-H97, H135-L213, H148-H204, H227-h231, H230-h234, H262-H322, H368-H426, h22-h98, h139-l214, h152-h208, h266-h326, h372-h430, L22-L87, L136-L195, l22-l90, l137-l196)
  TYPE      Peptide
REMARK      Product: D12177<US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of multiple myeloma
TARGET      TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
            CD3E [HSA:916] [KO:K06451]
  PATHWAY   hsa04060(608)  Cytokine-cytokine receptor interaction
            hsa04640(916)  Hematopoietic cell lineage
BRITE       USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Teclistamab
                D12177  Teclistamab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Tumor necrosis factor receptors
                TNFRSF17 (BCMA, CD269)
                 D12177  Teclistamab (USAN/INN) &lt;US&gt;
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3E
                 D12177  Teclistamab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12177
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12177
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12177
DBLINKS     CAS: 2119595-80-9
///
